Log in to save to my catalogue

Trial of Lixisenatide in Early Parkinson’s Disease

Trial of Lixisenatide in Early Parkinson’s Disease

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_hal_primary_oai_HAL_hal_04552147v1

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

Lixisenatide, a glucagon-like peptide-1 receptor agonist used for the treatment of diabetes, has shown neuroprotective properties in a mouse model of Parkinson's disease.
In this phase 2, double-blind, randomized, placebo-controlled trial, we assessed the effect of lixisenatide on the progression of motor disability in persons with Parkinson's d...

Alternative Titles

Full title

Trial of Lixisenatide in Early Parkinson’s Disease

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_hal_primary_oai_HAL_hal_04552147v1

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_hal_primary_oai_HAL_hal_04552147v1

Other Identifiers

ISSN

0028-4793,1533-4406

E-ISSN

1533-4406

DOI

10.1056/NEJMoa2312323

How to access this item